AstraZeneca Q2 lifted by oncology growth

AstraZeneca (AZN) posted second-quarter revenue of $15.4 billion, a 6% increase compared with the same period a year earlier. Management highlighted double-digit growth in the oncology portfolio as a key driver of the performance. This strength helped offset weakness in other areas of the business and supported the company’s decision to maintain its guidance for the full year.

Tagrisso, the company’s blockbuster oral cancer medicine, was a major contributor to the quarter. The drug generated $1.9 billion in revenue, underlining the central role of oncology products in AstraZeneca (AZN)’s current growth profile. Oncology was cited as underpinning both the quarterly results and expectations for the remainder of the year.

While oncology advanced, AstraZeneca (AZN)’s cardiometabolic franchise faced headwinds. Farxiga, a medicine for cardiometabolic diseases, delivered $1.8 billion in second-quarter sales, down 16% year-on-year. The decline followed the loss of the drug’s primary U.S. patent exclusivity in April, which increased competitive pressure in that market.

The contrasting trajectories of Tagrisso and Farxiga illustrate the company’s evolving product mix. Strong demand for newer oncology therapies is helping to counteract the impact of patent expiries in more mature franchises. This balance is central to AstraZeneca’s ability to sustain overall revenue growth while navigating lifecycle challenges for individual medicines.

AstraZeneca reiterated its full-year outlook, projecting revenue growth in the mid-to-high single digits and core earnings per share growth in the low double digits. The maintenance of guidance reflects management’s confidence that ongoing oncology momentum and other growth drivers can offset pressures from patent losses.

The company pointed to multiple late-stage clinical trial readouts expected later this year as an additional support for its growth strategy. These upcoming data events are seen as important for expanding and reinforcing the existing portfolio, particularly in oncology. The chief financial officer stated being very confident in achieving a longer-term revenue target of $80 billion, underscoring the company’s ambitions beyond the current fiscal year.